Ardelyx | ARDX - Cash And Equivalent


Ardelyx reported $42.72M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Abbott USD 8.52B 1.01B Dec/2025
Amgen USD 9.13B 316M Dec/2025
Ardelyx USD 42.72M 47.32M Sep/2025
aTyr Pharma USD 6.15M 11.07M Sep/2025
Corcept Therapeutics USD 120.49M 4.64M Dec/2025
Curis USD 10.14M 10.14M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
TG Therapeutics USD 178.32M 100.54M Sep/2025
United Therapeutics USD 1.56B 217M Dec/2025
Xoma USD 143.9M 7.68M Jun/2024